Summary
A single intravenous dose of cimetidine 200mg was administered to 6 patients with severe chronic renal failure one hour prior to haemodialysis. The plasma concentrations of cimetidine and its sulphoxide metabolite at the start of haemodialysis were 2.74±0.12 and 0.76±0.08 µg/ml, and after dialysis for 4h 1.08±0.10 and 0.51±0.08 µg/ml, respectively (mean ± SE). The average haemodialysis clearance (ClHDa) of cimetidine during dialysis was 46–92ml/min at a dialysate flow rate of 320ml/min and blood flow rates in the 6 patients between 160–240ml/min. The mean ClHDa of the sulphoxide metabolite was 44% higher than that of cimetidine, and ranged between 49–148ml/min. During haemodialysis the mean plasma elimination half-life (t1/2) of cimetidine was 3.24h (range 2.08–5.08) and of the sulphoxide metabolite 9.49h (range 4.70–14.39). There was a significant relationship between the elimination rate constant (β) and ClHDa of the sulphoxide metabolite (p<0.01), but no such relationship was found between β and ClHDa of cimetidine. However, there was a tendency to a relationship between β of cimetidine and the capacity to metabolise the drug, expressed as the ratio between the plasma concentrations of the sulphoxide metabolite and cimetidine after dialysis for 4h. These ratios ranged between 0.23–0.76, and the lowest ratio was seen in the patient with the lowest β value of cimetidine. Thus, the large variations in the plained by differences in their capacity to metabolise the drug. The mean total amount of cimetidine eliminated during dialysis was 27.3mg (range 17.9–31.8), which was 9.0–15.9% of the given dose. Between 12.2–21.2mg (mean 15.3) of the sulphoxide metabolite was eliminated in the dialysate. Major adjustment of the dose of cimetidine on days of dialysis is not necessary.
Similar content being viewed by others
References
Doherty CC, O'Connor FA, Buchanan KD, Sloan JM, Ardill JES, Mc Geown MG (1977) Peptic ulcer in renal failure. Abstract. Br Soc Gastroenterol 59
Shepherd AMM, Stewart WK, Wormsley KG (1973) Peptic ulceration in chronic renal failure. Lancet 1: 1357–1359
Ventkateswaran PS, Jeffers A, Hocken AG (1972) Gastric acid secretion in chronic renal failure. Br Med J 4: 22–23
Doherty CC, O'Connor FA, Buchanan KD, Mc Geown MG (1977) Cimetidine for duodenal ulceration in patients undergoing haemodialysis. Br Med J 2: 1506–1508
Jones RH, Levin MR, Parsons V (1979) Therapeutic effect of cimetidine in patients undergoing haemodialysis. Br Med J 1: 650–652
Bodemar G, Norlander B, Walan A (1981) Pharmacokinetics of cimetidine after single doses and during continuous treatment. Clin Pharmacokinet 6: 306–315
Burland WL, Duncan WAM, Hesselbo T, Mills JG, Sharpe PC, Haggie SJ, Wyllie JH (1975) Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man. Br J Clin Pharmacol 2: 481–486
Somogyi A, Rohner H-G, Gugler R (1980) Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. Clin Pharmacokinet 5: 84–94
Walkenstein SS, Dubb JW, Randolph WC, Westlake WJ, Stote RM, Intoccia AP (1978) Bioavailability of cimetidine in man. Gastroenterology 74: 360–365
Griffiths R, Lee RM, Taylor DC (1977) Kinetics of cimetidine in man and experimental animals. In: Burland WL, Simkins MA (eds) Cimetidine. Excerpta Medica, Amsterdam, pp 38–51
Spence RW, Celestin LR, De la Guardia R, Mac Mullen CA, Mc Cormick DA (1977) Short communication: Biliary secretion of cimetidine in man. In: Burland WL, Simkins MA (eds) Cimetidine Excerpta Medica, Amsterdam, pp 81–84
Taylor DC, Cresswell PR, Bartlett DC (1978) The metabolism and elimination of cimetidine, a histamine H2-receptor antagonist, in the rat, dog and man. Drug Metabol Disposit 6: 21–30
Ma KW, Brown DC, Masler DS, Silvis SE (1978) Effects of renal failure on blood levels of cimetidine. Gastroenterology 74: 473–477
Larsson R, Bodemar G, Norlander B (1979) Oral absorption of cimetidine and its clearance in patients with renal failure. Eur J Clin Pharmacol 15: 153–157
Larsson R, Norlander B, Bodemar G, Walan A (1981) Steady state kinetics and dosage requirements of cimetidine in renal failure. Clin Pharmacokinet 6: 316–325
Canavan JSF, Briggs JD (1977) Cimetidine clearance in renal failure. In: Burland WL, Simkins MA (eds) Cimetidine. Excerpta Medica, Amsterdam, pp 75–80
Vaziri ND, Ness RL, Barton CH (1978) Hemodialysis clearance of cimetidine. Arch Intern Med 138: 1685–1686
Fawcett JK, Scott JE (1960) A rapid and precise method for the determination or urea. J Clin Pathol 13: 156–159
Lee RM, Osborne PM (1978) High-pressure liquid chromatographic determination of cimetidine sulphoxide in human blood and urine. J Chromatogr 146: 354–360
Strouth L (1980) Personal communication
Wolf AV, Remp DG, Kiley JE, Currie GD (1951) Artificial kidney function: Kinetics of hemodialysis. J Clin Invest 30: 1062–1070
Sargent JA, Gotch FA (1978) Principles and biophysics of dialysis. In: Drukker W, Parsons FM, Maher JF (eds) Replacement of renal function by dialysis. Martinus Nijhoff, Hague, pp 38–68
Lee CS, Marbury TC, Benet LZ (1980) Clearance calculations in hemodialysis: Application to blood, plasma and dialysate measurements for ethambutol. J Pharmacokinet Biopharmaceut 8: 69–81
Gibson TP, Matusik E, Nelson LD, Briggs WA (1976) Artificial kidneys and clearance calculations. Clin Pharmacol Ther 20: 720–726
Krichman KH, Cutler RE, Blair AD (1979) Pharmacokinetics of cimetidine in normal and uremic humans. Clin Res 27: 1, 73A
Randolph WC, Osborne VL, Intoccia AP (1980) Cimetidine sulphoxide: Whole blood levels in normal human subjects and patients with varying degrees of renal failure. Pharmacologist 22: 278, 649A
Puurunen J, Sotaniemi E, Pelkonen O (1980) Effect of cimetidine on microsomal drug metabolism in man. Eur J Clin Pharmacol 18: 185–187
Flind AC (1978) Cimetidine and oral anticoagulants. Lancet 2: 1054
Silver BA, Bell WR (1979) Cimetidine potentiation of the hypoprothrombinemic effect of warfarin. Ann Int Med 90: 348–349
Sjöqvist F, von Bahr C (1973) Interindividual differences in drug oxidation: Clinical importance. Drug Metabol Disposit 1: 469–482
Levi AJ, Sherlock S, Walker D (1968) Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet 1: 1275–1279
Maddocks JL, Wake CJ, Harber MJ (1975) The plasma half-life of antipyrine in chronic uremic and normal subjects. Br J Clin Pharmacol 2: 339–343
Testa B, Jenner P (eds) (1976) Drug metabolism: Chemical and biochemical aspects. Marcel Decker, New York, pp 298
Delaney JC, Ravey M (1977) Cimetidine and mental confusion. Lancet 2: 512
Grave W, Nadorp JHSM, Rutten JJMH (1977) Cimetidine and renal failure. Lancet 2: 719–720
Vickery TR (1978) Cimetidine reaction. Drug Intell Clin Pharmacol 12: 242
Wood CA, Isacson ML, Hibbs MS (1978) Cimetidine and mental confusion. J Am Med Assoc 239: 2550–2551
Schentag JJ, Cerra FB, Calleri G, De Glopper E, Rose JQ, Bernhard H (1979) Pharmacokinetic and clinical studies in patients with cimetidine — associated mental confusion. Lancet 1: 177–181
Mills JG, Smith, Kline and French Research Ltd (1981) Personal communication
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Larsson, R., Erlanson, P., Bodemar, G. et al. Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis. Eur J Clin Pharmacol 21, 325–330 (1982). https://doi.org/10.1007/BF00637621
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00637621